TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 YTD Q2 P&L / Income Statement

TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

296,782,000 US dollars

Cost of goods sold

4,123,000 US dollars

Gross profit (calculated)

292,659,000 US dollars

Operating expenses (calculated)

325,620,000 US dollars

Operating income (loss)

negative 32,961,000 US dollars

Total other (expense) income, net

negative 38,762,000 US dollars

Loss from continuing operations before income tax

negative 71,723,000 US dollars

Income tax benefit (provision) on continuing operations

negative 324,000 US dollars

Net loss

negative 71,899,000 US dollars

FILSPARI

246,230,000 US dollars

Tiopronin products

39,614,000 US dollars

License and collaboration revenue

10,938,000 US dollars

Selling, general and administrative

176,366,000 US dollars

Research and development

117,377,000 US dollars

Royalty expense

31,877,000 US dollars

Loss from discontinued operations, net of tax

negative 500,000 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.